secwatch.observer — SEC 8-K summary
======================================

Issuer:     KIORA PHARMACEUTICALS INC (KPRX)
CIK:        0001372514
Form:       8-K
Filed at:   2024-03-25T23:59:59+00:00
Accession:  0001372514-24-000027
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiora reports 2023 net loss $12.5M; cash >$30M post partnership and placement
-----------------------------------------------------------------------------

- Net loss $12.5M in 2023 vs $13.6M in 2022; R&D expense $4.0M, G&A $4.7M.
- Cash and equivalents $2.5M at year-end 2023; $16M upfront from TOI partnership and $13.8M private placement net proceeds in Feb 2024 raised cash >$30M.
- Company expects existing cash to fund operations through 2026.
- KIO-301 Phase 2 trial in retinitis pigmentosa expected to start Q4 2024; KIO-104 Phase 2 planning underway.
- Partnership with Théa Open Innovation grants exclusive rights to KIO-301 outside Asia; potential milestones up to $285M plus tiered royalties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372514/000137251424000027/0001372514-24-000027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372514/000137251424000027/kprx-20240325.htm
  HTML page:      https://secwatch.observer/filing/0001372514-24-000027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer